Commemorating 40 Years of Recombinant Hepatitis B Vaccines: Past Successes, Current Challenges and Future Directions in Therapeutic Vaccine Development
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Hepatitis Virus Vaccines".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 231
Editors
Interests: characterization of newly emerged viruses and hepatitis viruses; development of antibodies for diagnostic and therapeutic applications; protein engineering
Special Issues, Collections and Topics in MDPI journals
Interests: coronavirus; SARS-CoV-2; variant of concern; vaccine evaluation; T lymphocytes; HBV
Special Issues, Collections and Topics in MDPI journals
Interests: occult hepatitis B virus infection (OBI); HBV S protein/transmembrane-domain mutations; ER stress (PERK–eIF2α–ATF4 pathway); viral immune escape/serology; HBV-related hepatocellular carcinoma (HCC); molecular diagnostics in transfusion medicine; hepatitis C virus (HCV) genotyping & RAS; blood donor screening/immunoassays
Special Issue Information
Dear Colleagues,
Engerix B/Recombivax HB is a non-replicative subunit vaccine produced in Saccharomyces cerevisiae cells and indicated for the active immunization of individuals of all ages. It was the first recombinant hepatitis B vaccine approved for human use and was introduced to the market in 1986.
The prophylactic HBV vaccine (proHBVac) is safe and highly immunogenic, achieving over 90% seroconversion with protective anti-HBs antibody titers. Immune memory against HBV is sustained after vaccination. Under national immunization programs, proHBVac has significantly reduced HBsAg positivity in the Y, Z and Alpha generations born in the past four decades.
Since HBV persistence in chronic patients is associated with the development of immune tolerance and a lack of functional HBV-specific T cells, restimulating anti-HBV immunity with therapeutic hepatitis B vaccines (theHBVac) could be a potential treatment option. As protein-based HBV vaccines have not produced the anticipated outcome so far, the development of the HBVac capable of inducing more potent immune responses is needed.
We invite you to submit research articles, reviews, case reports and clinical trial data related to proHBVac- and theHBVac-related topics, including genetic polymorphisms, immune cell responses, humoral and adaptive immunity, and novel vaccine development. We also welcome manuscripts discussing lessons learned from current epidemiological data in large cohorts of vaccinees.
We look forward to receiving your contributions.
Dr. Yee-Joo Tan
Dr. Bingqian Qu
Guest Editors
Dr. Xinyi Jiang
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatitis B virus
- prophylactic and therapeutic hepatitis B vaccines
- immune response
- novel vaccine development
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
